2025-08146RuleWallet

FDA Approves CMV Test for Baby Virus Hunt

Published Date: 5/9/2025

Rule

Summary

The FDA is officially classifying a special test that detects cytomegalovirus (CMV) in newborns as a Class II device, meaning it has special safety rules but is easier to get to patients. This change helps make sure the test is safe and effective while speeding up access to this important tool for babies and families. The new rules took effect on May 9, 2025, and could lower costs and delays for companies making these tests.

Analyzed Economic Effects

5 provisions identified: 4 benefits, 1 costs, 0 mixed.

Newborn CMV Test Moved to Class II

The FDA classified the cytomegalovirus (CMV) nucleic acid detection device for diagnosing congenital CMV in newborns as Class II (special controls). The order is effective May 9, 2025, and the classification was applicable on November 30, 2018. FDA says this classification provides reasonable assurance of safety and will enhance patients' access to the test by reducing regulatory burdens.

Easier Market Path for Test Makers

By classifying this device as Class II via the De Novo process, FDA says the device can serve as a predicate for future devices and that this classification will reduce regulatory burdens and may lower costs and delays for companies making these tests.

Detailed Clinical and Design Study Requirements

The special controls require device sponsors to provide detailed design verification and validation, analytical studies (limit of detection, inclusivity, cross-reactivity, stability), and clinical study documentation that demonstrates sensitivity and specificity. Clinical study subjects must be consistent with the intended use population (infants younger than 21 days of age), results must be compared to FDA-accepted comparator methods, and if positive samples are insufficient sponsors must evaluate additional pre-selected positive samples.

Breastfeeding Timing Requirement for Samples

Labeling must include a statement that breast milk can cause false positive saliva results if samples are collected less than 1 hour after breastfeeding. The labeling must recommend collecting samples a minimum of 1 hour after breastfeeding.

Test Result Interpretation Warnings

Labeling must state that negative CMV test results do not rule out infection and should not be the sole basis for diagnosis or treatment, and that positive results should be interpreted with other clinical and laboratory information.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
5/9/2025
5/9/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register